Cargando…

The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease

INTRODUCTION: The purpose of this study was to analyze the effects of hypoxia-inducible factor (HIF) stabilizers on anemia in non-dialysis-dependent (NDD) and dialysis-dependent (DD) chronic kidney disease (CKD) patients. METHODS: Published studies were extracted from PubMed, China Biological Medici...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Hongzhen, Zhou, Tianbiao, Li, Hongyan, Zhong, Zhiqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151102/ https://www.ncbi.nlm.nih.gov/pubmed/30271115 http://dx.doi.org/10.2147/DDDT.S175887

Ejemplares similares

A rare case report of heavy dose colchicine induced acute kidney injury
por: Zhong, Hongzhen, et al.
Publicado: (2018)

Clinical efficacy and safety of rituximab in lupus nephritis
por: Zhong, Zhiqing, et al.
Publicado: (2019)

Association of apoE gene polymorphisms with lipid metabolism in renal diseases
por: Zhou, Tianbiao, et al.
Publicado: (2020)

Association of Nuclear Receptor Coactivators with Hypoxia-Inducible Factor-1α in the Serum of Patients with Chronic Kidney Disease
por: Zhou, Tianbiao, et al.
Publicado: (2020)

Meta-analysis of associations of vascular endothelial growth factor protein levels and -634G/C polymorphism with systemic lupus erythematosus susceptibility
por: Tang, Wenzhuang, et al.
Publicado: (2019)

Relationship between transforming growth factor-β1 and type 2 diabetic nephropathy risk in Chinese population
por: Zhou, Tianbiao, et al.
Publicado: (2018)

A systematic review and meta-analyses of the relationship between glutathione S-transferase gene polymorphisms and renal cell carcinoma susceptibility
por: Zhong, Zhiqing, et al.
Publicado: (2018)

Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease
por: Kaplan, Joshua M., et al.
Publicado: (2018)

Association of hypoxia-inducible factor-1α (HIF1α) 1790G/A gene polymorphism with renal cell carcinoma and prostate cancer susceptibility: a meta-analysis
por: Li, Hong-Yan, et al.
Publicado: (2019)

Association of Methylenetetrahydrofolate Reductase, Vitamin D Receptor, and Interleukin-16 Gene Polymorphisms With Renal Cell Carcinoma Risk
por: Zhou, Tianbiao, et al.
Publicado: (2019)

Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis
por: Zhong, Hongzhen, et al.
Publicado: (2020)

Efficacy and safety of cyclosporine a for patients with steroid-resistant nephrotic syndrome: a meta-analysis
por: Li, Hong-Yan, et al.
Publicado: (2019)

The Efficacy of Mesenchymal Stem Cells in Therapy of Acute Kidney Injury Induced by Ischemia-Reperfusion in Animal Models
por: Zhou, Tianbiao, et al.
Publicado: (2020)

All-trans retinoic acid regulating angiopoietins-1 and alleviating extracellular matrix accumulation in interstitial fibrosis rats
por: Zhong, Zhiqing, et al.
Publicado: (2021)

Association of Glutathione S-transferase gene polymorphism with bladder Cancer susceptibility
por: Zhou, Tianbiao, et al.
Publicado: (2018)

Effects of hypoxia on bone metabolism and anemia in patients with chronic kidney disease
por: Kan, Chao, et al.
Publicado: (2021)

The impacts of hypoxia-inducible factor stabilizers on laboratory parameters and clinical outcomes in chronic kidney disease patients with renal anemia: a systematic review and meta-analysis
por: Takkavatakarn, Kullaya, et al.
Publicado: (2023)

Rituximab therapy in adults with steroid-dependent nephrotic syndrome
por: Zhong, Hongzhen, et al.
Publicado: (2019)

Anemia and Hypoxia Impact on Chronic Kidney Disease Onset and Progression: Review and Updates
por: Habas, Elmukhtar, et al.
Publicado: (2023)

An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease
por: Zhao, Hanxue, et al.
Publicado: (2023)

The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia
por: Landau, Daniel, et al.
Publicado: (2018)

Evolution of hypoxia and hypoxia-inducible factor asparaginyl hydroxylase regulation in chronic kidney disease
por: Faivre, Anna, et al.
Publicado: (2023)

Hypoxia Induced Factor in Chronic Kidney Disease: Friend or Foe?
por: Li, Weiying, et al.
Publicado: (2018)

The role of roxadustat in chronic kidney disease patients complicated with anemia
por: Liu, Jie, et al.
Publicado: (2023)

Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia
por: Li, Jing, et al.
Publicado: (2022)

Renal Anemia - Risk Factor for Chronic Kidney Disease
por: Cană-Ruiu, Daniela, et al.
Publicado: (2013)

Hypoxia-Inducible Factor Stabilizers in End Stage Kidney Disease: “Can the Promise Be Kept?”
por: Crugliano, Giuseppina, et al.
Publicado: (2021)

Efficacy of mesenchymal stem cells in animal models of lupus nephritis: a meta-analysis
por: Zhou, Tianbiao, et al.
Publicado: (2020)

An Overview of Safety and Efficacy Between Hypoxia-Inducible Factor-Prolyl-Hydroxylase Inhibitors and Erythropoietin-Stimulating Agents in Treating Anemia in Chronic Kidney Disease Patients
por: Sonia, Shamsun Nahar, et al.
Publicado: (2023)

Association of vascular endothelial growth factor (VEGF) protein levels and gene polymorphism with the risk of chronic kidney disease
por: Liu, Yipin, et al.
Publicado: (2022)

Hypoxia and Hypoxia-Inducible Factors in Kidney Injury and Repair
por: Shu, Shaoqun, et al.
Publicado: (2019)

Hypoxia and chronic kidney disease
por: Wang, Bin, et al.
Publicado: (2022)

Anemia in children with chronic kidney disease
por: Koshy, Susan M., et al.
Publicado: (2007)

Anemia, Diabetes, and Chronic Kidney Disease
por: Mehdi, Uzma, et al.
Publicado: (2009)

Treatment of anemia in chronic kidney disease: known, unknown, and both
por: Foley, Robert N
Publicado: (2011)

The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease
por: Yarnoff, Benjamin O., et al.
Publicado: (2016)

Bibliometric analysis of hypoxia inducible factor prolyl hydroxylase inhibitor in anemia
por: Zheng, Li, et al.
Publicado: (2022)

The role of indoxyl sulfate in renal anemia in patients with chronic kidney disease
por: Wu, Chih-Jen, et al.
Publicado: (2017)

Mesenchymal stem cells: A new therapeutic tool for chronic kidney disease
por: Wang, Jiali, et al.
Publicado: (2022)

Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG‐4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo‐Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients
por: Provenzano, Robert, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cqhp7i4mgh08ra1694vp8e0n3t